Proteo Inc (PTEO) 0.0800 $PTEO
Lung Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhlntx/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2014" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Lung Transplantation Overview Therapeutics Development Pipeline Products for Lung Transplantation - Overview Pipeline Products for Lung Transplantation - Comparative Analysis Lung Transplantation - Therapeutics under Development by Companies Lung Transplantation - Pipeline Products Glance Late Stage Products Early Stage Products Lung Transplantation - Companies Involved in Therapeutics Development Lung Transplantation - Therapeutics Assessment Drug Profiles cyclosporine - Drug Profile EZ-2053 - Drug Profile Elafin - Drug Profile Respiratory and Inflammatory Diseases Program - Drug Profile VR-909 - Drug Profile Lung Transplantation - Recent Pipeline Updates Lung Transplantation - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Quark Pharmaceuticals, Inc. Vectura Group plc Proteo, Inc. APT Pharmaceuticals, Inc. (Inactive) Neopharm Ltd. For more information visit http://www.researchandmarkets.com/research/lhlntx/lung About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Signal Daily Stock Watch - Proteo Inc. (OTCQB: PTEO)
WorldStockWire - Tue Sep 03, 9:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lung Transplantation - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:28AM CDT
Research and Markets has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2013" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transpl
Proteo, Inc. /Proteo Biotech AG: FDA Grants Orphan Drug Designation to Elafin for Prevention of Inflammatory Complications of Transthoracic Esophagectomy
Business Wire - Wed Mar 20, 12:41PM CDT
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the prevention of inflammatory complications of transthoracic esophagectomy.
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension
Business Wire - Thu Jan 10, 7:00AM CST
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the treatment of pulmonary arterial hypertension.
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
Lung Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhlntx/lung) has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2014" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Lung Transplantation Overview Therapeutics Development Pipeline Products for Lung Transplantation - Overview Pipeline Products for Lung Transplantation - Comparative Analysis Lung Transplantation - Therapeutics under Development by Companies Lung Transplantation - Pipeline Products Glance Late Stage Products Early Stage Products Lung Transplantation - Companies Involved in Therapeutics Development Lung Transplantation - Therapeutics Assessment Drug Profiles cyclosporine - Drug Profile EZ-2053 - Drug Profile Elafin - Drug Profile Respiratory and Inflammatory Diseases Program - Drug Profile VR-909 - Drug Profile Lung Transplantation - Recent Pipeline Updates Lung Transplantation - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Quark Pharmaceuticals, Inc. Vectura Group plc Proteo, Inc. APT Pharmaceuticals, Inc. (Inactive) Neopharm Ltd. For more information visit http://www.researchandmarkets.com/research/lhlntx/lung About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Signal Daily Stock Watch - Proteo Inc. (OTCQB: PTEO)
WorldStockWire - Tue Sep 03, 9:30PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Lung Transplantation - Pipeline Review, H1 2013
M2 - Fri Apr 12, 5:28AM CDT
Research and Markets has announced the addition of the "Lung Transplantation - Pipeline Review, H1 2013" report to their offering. 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Lung Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Transplantation. Scope - A snapshot of the global therapeutic scenario for Lung Transplantation. - A review of the Lung Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Transpl
Proteo, Inc. /Proteo Biotech AG: FDA Grants Orphan Drug Designation to Elafin for Prevention of Inflammatory Complications of Transthoracic Esophagectomy
Business Wire - Wed Mar 20, 12:41PM CDT
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the prevention of inflammatory complications of transthoracic esophagectomy.
Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension
Business Wire - Thu Jan 10, 7:00AM CST
Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the treatment of pulmonary arterial hypertension.
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
